214 related articles for article (PubMed ID: 22353811)
1. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
2. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Horn L; Dahlberg SE; Sandler AB; Dowlati A; Moore DF; Murren JR; Schiller JH
J Clin Oncol; 2009 Dec; 27(35):6006-11. PubMed ID: 19826110
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Lee SM; Woll PJ; Rudd R; Ferry D; O'Brien M; Middleton G; Spiro S; James L; Ali K; Jitlal M; Hackshaw A
J Natl Cancer Inst; 2009 Aug; 101(15):1049-57. PubMed ID: 19608997
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitors in the treatment of lung cancer.
Shepherd FA
Lung Cancer; 2001 Dec; 34 Suppl 3():S81-9. PubMed ID: 11740999
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
Dudek AZ; Lesniewski-Kmak K; Larson T; Dragnev K; Isaksson R; Gupta V; Maddaus MA; Kratzke RA
J Thorac Oncol; 2009 Aug; 4(8):969-75. PubMed ID: 19633472
[TBL] [Abstract][Full Text] [Related]
8. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
[TBL] [Abstract][Full Text] [Related]
9. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Dudek AZ; Mahaseth H
Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
11. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Najjar F; Al-Massarani G; Banat I; Alammar M
Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Gualberto A; Hixon ML; Karp DD; Li D; Green S; Dolled-Filhart M; Paz-Ares LG; Novello S; Blakely J; Langer CJ; Pollak MN
Br J Cancer; 2011 Jan; 104(1):68-74. PubMed ID: 21102589
[TBL] [Abstract][Full Text] [Related]
13. Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Musallam KM; Taher AT
J Natl Cancer Inst; 2009 Dec; 101(23):1657; author reply 1657-8. PubMed ID: 19858426
[No Abstract] [Full Text] [Related]
14. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006; 24(5):492-6. PubMed ID: 16939957
[TBL] [Abstract][Full Text] [Related]
15. A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial.
Lee SM; Hackshaw A
Cancer Med; 2013 Jun; 2(3):360-6. PubMed ID: 23930213
[TBL] [Abstract][Full Text] [Related]
16. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
Lee SM; Rudd R; Woll PJ; Ottensmeier C; Gilligan D; Price A; Spiro S; Gower N; Jitlal M; Hackshaw A
J Clin Oncol; 2009 Nov; 27(31):5248-54. PubMed ID: 19770378
[TBL] [Abstract][Full Text] [Related]
17. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
[TBL] [Abstract][Full Text] [Related]
18. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Hanrahan EO; Ryan AJ; Mann H; Kennedy SJ; Langmuir P; Natale RB; Herbst RS; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3600-9. PubMed ID: 19447868
[TBL] [Abstract][Full Text] [Related]
19. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
